- Tags: retina
Products
FDA approves Lupin's Lucentis biosimilar injection
Ranluspec (ranibizumab-hkdz) marks the third ranibizumab biosimilar cleared in the U.S. to treat five retinal indications.
Pipeline
Oculis's phase 3 DME eye drop trial fails primary goals
While OCS-01 was well-tolerated, the DIAMOND program did not meet either outcome measures; company will not seek an FDA NDA filing.
Business
Lexitas acquires Erie Retina Research to expand ophthalmic trials
Partnership also involves integration of CASExERIE and Element Erie: Imaging and Reading Center to establish a fully integrated retina research platform.
Business
NeuroVision expands retinal imaging-based neurodegenerative disease detection with new acquisition
Retinal imaging developer adds Durin Life Sciences’ noninvasive, blood-based biomarker test to its integrated platform targeting cognitive diseases.
Research
Vitreous floaters may predict RD development
Cohort study finds new-onset floaters, particularly when acute or numerous, confer a higher absolute risk of retinal detachment than flashes alone.
Products
Remidio's portable fundus camera offers point-of-care imaging
FDA-cleared and smartphone-based diagnostic device offers complete imaging for both eyes in less than 1 minute—across a wide range of clinical settings.
Research
Oculis's global DME consensus study identifies critical gaps in care
Expert panel highlights disease management while emphasizing the importance of early intervention and non-invasive treatment options based on BCVA outcomes.
Pipeline
Atsena releases positive XLRS interim data from LIGHTHOUSE study
Enrollment for Part C of the study is underway, with the company targeting a 2028 BLA submission for ATSN-201, an investigational gene therapy.
Events
ARVO 2026 signals a turning point for retina innovations
Highlights from this year’s research in vision and ophthalmology meeting covered genetics, gene editing, AI, advanced imaging, and more.
Events
Retina Summit 2026: DR referrals and genetic testing for ODs
AAO’s one-day meeting explored retina care’s shift from referral-based to decision-making at the OD level.
Pipeline
MeiraGTx acquires J&J's XLRP investigational therapy
Deal includes all interests in botaretigene sparoparvovec (bota-vec); company plans to immediately file for global regulatory approval.
Pipeline
Belite Bio begins rolling NDA submission of oral tinlarebant for Stargardt
Full submission planned for Q2 2026, once-daily tablet has potential to become the first-ever treatment approved for this patient base.
Research
Maternal diabetes exposure increases severe ROP risk
In-utero exposure to maternal diabetes may raise the odds, even in infants who appear lower risk by traditional measures.
Events
Retina Summit 2026: OD updates for AMD management and imaging
Key takeaways from AAO’s one-day meeting explore retina care’s shift from referral-based to decision-making at the OD level.
Pipeline
Ocular Therapeutix releases additional phase 3 AXPAXLI data for wet AMD
Data from SOL-1 phase 3 data will become the basis of a planned NDA submission in near future.
Research
Does smoking age your eyes?
Mouse model study finds cigarette smoke may cause changes in eye cells similar to aging damage, with younger and older cells differing in protection.
Pipeline
FDA accepts Outlook Therapeutics' request over rejected wet AMD BLA
Company challenges decision on failed third submission package of ONS-5010 / LYTENAVA (bevacizumab-vikg), with a decision expected in May.
Research
Severe DR linked to higher dementia risk
Association reinforces the potential role of routine eye exams in early cognitive screening.
Products
FDA clears Bausch + Lomb's Bi-Blade+ vitrectomy cutter and fluidics technology
Dual-port vitrectomy cutter increases cutting speed from 15K to 25K per minute, while Adaptive Fluidics update expands capabilities of the Stellaris Elite system
Research